Deep brain stimulation in early stage Parkinson's disease may reduce the relative risk of symptom worsening-Reference-Cited by-同舟云学术

Deep brain stimulation in early stage Parkinson's disease may reduce the relative risk of symptom worsening

Published:2016-01 Issue: Volume:22 Page:112-113
ISSN:1353-8020
Container-title:Parkinsonism & Related Disorders
language:en
Short-container-title:Parkinsonism & Related Disorders

Author:

Hacker Mallory^ORCID,Charles David,Finder Stuart

Publisher

Elsevier BV

Subject

Clinical Neurology,Geriatrics and Gerontology,Neurology

Reference5 articles.

1. Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease;Charles;Park. Relat. Disord.,2014

2. Deep brain stimulation in early stage Parkinson's disease: operative experience from a prospective randomised clinical trial;Kahn;J. Neurol. Neurosurg. Psychiatry,2011

3. Potential subjects' responses to an ethics questionnaire in a phase 1 study of deep-brain stimulation in early Parkinson's disease;Finder;J. Clin. Ethics,2012

4. Fortitude and Community: Response to Yee and Ford;Finder,2012

5. Deep brain stimulation in early Parkinson's disease: enrollment experience from a pilot trial;Charles;Park. Relat. Disord.,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson’s Disease;ACS Medicinal Chemistry Letters;2018-10-16

2. Discovery, Structure–Activity Relationship, and Biological Characterization of a Novel Series of 6-((1H-Pyrazolo[4,3-b]pyridin-3-yl)amino)-benzo[d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu4);Journal of Medicinal Chemistry;2018-09-24

3. Expanding indications for deep brain stimulation;Neurology India;2018

4. New neurosurgical approaches for tremor and Parkinson's disease;Current Opinion in Neurology;2017-08

5. Shaking Up the Debate: Ensuring the Ethical Use of DBS Intervention Criteria for Mid-Stage Parkinson’s Patients;Neuromodulation: Technology at the Neural Interface;2017-07